<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544206</url>
  </required_header>
  <id_info>
    <org_study_id>BK07</org_study_id>
    <nct_id>NCT00544206</nct_id>
  </id_info>
  <brief_title>Comparison of Enteral Products for Tube Fed Patients With Type 2 Diabetes</brief_title>
  <official_title>Comparison of Enteral Products for Tube Fed Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the glucose response in tube fed subjects with type 2 diabetes of a standard
      enteral product to that of a diabetes-specific enteral product
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean glucose level</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting capillary blood glucose level;percentage change from baseline in the dose and amount of antihyperglycemic medication(s), including insulin</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>#1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetes specific enteral feeding product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>#2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard enteral feeding product</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard enteral feeding product</intervention_name>
    <description>16 hrs daily x 5 days</description>
    <arm_group_label>#2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diabetes specific feeding product</intervention_name>
    <description>16 hrs daily for 5 days</description>
    <arm_group_label>#1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed and dated informed consent

          -  diagnosis of type 2 diabetes

          -  HbA1c between 7.0 and 9.0%

          -  18 - 75 years of age

          -  currently receiving a standard enteral product

          -  anticipated duration on tube feeding at least one month

          -  100% of patient's nutrient and energy needs are anticipated to be met by enteral
             nutrition support

          -  anticipated life expectancy is more than or equal to 6 months

          -  free of infections

          -  no change in medications within 2 weeks prior to screening that could profoundly
             affect blood glucose

        Exclusion Criteria:

          -  composition of either product is inappropriate for the patient due to allergies or
             intolerance to any ingredient found in the study products

          -  composition of either product is inappropriate for the patient due to protein, fluid
             or electrolyte restrictions for concomitant conditions

          -  significant cardiovascular event less than or equal to 2 weeks prior to study entry

          -  major surgery less than or equal to 2 weeks prior to study entry

          -  pre-planned surgery during the study period

          -  active malignancy, including melanoma and excluding cutaneous malignancies

          -  severe dementia

          -  known allergies to medical grade adhesives and/or skin disinfectants

          -  taking octreotide

          -  chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or
             C, or HIV

          -  participation in a concomitant trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Sacks, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2007</study_first_submitted>
  <study_first_submitted_qc>October 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>September 22, 2008</last_update_submitted>
  <last_update_submitted_qc>September 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director Clinical Research Operations</name_title>
    <organization>Abbott Nutrition</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

